No one wants to talk about constipation. Except AstraZeneca. On national television. To the tune of almost $10 million in media spending since late June, according to real-time TV ad tracker iSpot.tv.
Novartis' newly acquired Arzerra (ofatumumab) is up against some hefty competition in chronic lymphocytic leukemia (CLL). But the Swiss drugmaker has a plan for helping it achieve its sales potential. Read more >>
Sex sells and Sprout's Addyi is likely to do just that. But it won't be thanks to any formal advertising, at least at first. Sprout got approved for Addyi, the first drug to treat low female sex drive this week, but part of its agreement with the FDA means it's not allowed to market or advertise the drug for 18 months. Read more >>
Medivation made a name for itself with Xtandi, the prostate cancer med that's now giving Johnson & Johnson's Zytiga a run for its money. Now, it wants to challenge other drugmakers in the PARP inhibitor field, too.
The drama is on for Boehringer Ingelheim. On TV, that is. The pharma has struck a deal with a Telemundo telenovela set in Los Angeles called "Bajo el Mismo Cielo" for a diabetes awareness campaign--and with it, BI becomes the first drugmaker with an integrated storyline on the Spanish language channel.
Sorry, Victoza. Novo Nordisk has given up on the GLP-1 drug as a treatment for Type 1 diabetes, at least for now. A blockbuster in the Type 2 form of the disease, Victoza fell short in a new late-stage trial as an add-on to insulin therapy.
Female libido drug Addyi from Sprout stirred up its fair share of controversy last week with its FDA green light, which came despite serious potential side effects such as severe drowsiness, nausea and dizziness. But if it can succeed despite those side effect worries, it certainly wouldn't be the first drug to do so.
Eli Lilly has fought tooth and nail to protect a patent for its blockbuster cancer drug Alimta, chalking up some victories in the U.S. despite setbacks overseas. Now the company is celebrating a big win as a federal court ruled in its favor, granting Lilly 5 more years of Alimta exclusivity in the U.S.
Here we go again. Another public opinion pool where Big Pharma shows up among the least likable industries or lands near the bottom when it comes to corporate industry reputation. This time it's the monthly Kaiser Family Foundation health tracking poll for August. While the core of the study focused on consumers' opinions about drug prices, several questions also tallied public sentiment regarding pharma. And it ain't good.